Oxis Isle of Man, Limited

Tetrahedron

Oxis International S.a.

Galderma Research & Development

Tetrahedron Sas

Oxis Therapeutics Inc.

Marc E Moutet

Jean-Claude Y Yadan

Jean R Chaudiere

Irene Erdelmeier

Catherine Tailhan-Lomont

Jinzhu Xu

Irène Erdelmeier

Claire Banissi

Allen Hopper

Georges App&eacute;r&eacute;

Irène Erdelmeir

Remi Lebel

Jean-Claude Michel

The invention relates to a selenium compound. Said selenium compound has formula (I), where R=alkyl; R=H, RC(=0), ROC(=0), a-aminoacyl, CHSeCHCHCH(NH)C(=0), CHSeCHCHCH(OH)C(=0); X=OH, OR, NH, NRR, &#x3b1;-amino acid, CHSeCHCHCH(COOH)NH&#x2014;, CHSeCHCHCH(COOH)0-; R=alkyl; R=alkyl, aryl; R=H, alkyl, aryl; Rand Rwhich can together form a 5- or 6-membered cycloalkyl radical which can comprise a heteroatom; provided that when X=NH-terbutyl, R&#x2260;C(=0)CH. Said compound can be used as a pharmaceutical substance, in particular as an antitumour substance.

Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents

Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.

Pharmaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith

The invention relates to the enrichment of non-photosynthetic micro-organisms with organic selenium, and more particularly with selenomethionine, from a compound of the seleno-hydroxyacid type such as 2-hydroxy-4-methylseleno-butanoic acid in the (D, L) form or in the form of an enantiomer, salt, ester, or amide derivative of said compound, and to the use of micro-organisms, particularly bacteria thus enriched in the fields of animal or human nutrition, cosmetics, or pharmaceuticals.

Non-photosynthetic micro-organisms enriched with organic selenium from seleno-hydroxyacid compounds and applications thereof in the field of nutrition, cosmetics and pharmacueuticals

The present invention relates to a novel process for preparing 2-hydroxy-4-methylselenobutyric acid from 3-methylselenoproprion-aldehyde. The 2-hydroxy-4-methylselenobutyric acid is obtained alone or as a mixture with its sulphur-containing analogue. The invention also relates to the compositions, in particular nutritional compositions, comprising a mixture of 2-hydroxy-4-methylselenobutyric acid and 2-hydroxy-4-methylthiobutyric acid, and a physiologically acceptable medium, and to the use of this mixture as a dietary ingredient.

Process for preparing 2-hydroxy-4-methylselenobutyric acid, alone or as a mixture with its sulphur-containing analogue, and uses thereof in nutrition, in particular animal nutrition

The purpose of this invention is: The new compounds that are the subject of this invention satisfy the general formula (I): in which

Selenohydroxy acids and their derivatives, applications in nutrition, cosmetics and pharmaceutics

The invention is directed to novel cyclic organoselenium compounds useful as antioxidants, pharmaceutical compositions containing them, and methods for their preparation.

Cyclic organoselenium compounds, their preparation and their uses

The present invention broadly relates to racemic or optically active 5-substituted 3,4-dihydroxy-2(5H)-furanone compounds and their pharmaceutically acceptable salts, useful for treating a pathology in which reactive oxygen species and inflammatory mediators are contributing deleterious factors, such as acute or chronic inflammatory disorders, for example, asthma, rheumatoid arthritis, inflammatory bowel disease, and acute respiratory distress syndrome; neurodegenerative disorders, such as Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, traumatic brain injury and multiple sclerosis; cardiovascular diseases, such as atherosclerosis; viral diseases, such as AIDS; skin diseases, such as psoriasis, sunburn and premature aging; and eye diseases, such as glaucoma, cataract, senile macular degeneration, inflammatory eye conditions, trauma, post-traumatic eye disorders, diabetic retinopathy, and eye infections.

Substituted 5-biphenyl-3,4-dihydroxy-2(5H)-furanones and method of use therefor

The invention concerns novel benzisoselen-azoline and -azine derivatives. These novel derivatives have the following general formula (II): ##STR1## where: R.sup.1 to R.sup.8 and R.sup.10 have various meanings, in particular H, alkyl, etc . . . ; ##STR2## Y.sup.- represents the anion of a pharmaceutically acceptable anion; n=0, 1; m=0, 1, 2; p=1, 2, 3; q=2, 3, 4; r=0, 1; and their pharmaceutically acceptable salts of acids or bases; there being no more than one substituent R.sup.9 in each molecule with general formula II. These novel derivatives can be used in medication.

Method for storing a biological organ transplant graft using a

The invention relates to 2-mercaptoimidazole derivatives substituted in the 4(or 5)-position. These 2-mercaptoimidazole derivatives are of the general formula (I) below: ##STR1## wherein: R.sub.1, R.sub.2, R.sub.5, R.sub.7 and R.sub.8 are hydrogen, a lower alkyl, an aralkyl or a substituted aralkyl, wherein at least one of R.sub.1 and R.sub.2 is hydrogen;

Growing community of inventors

Bagneux, France

Marc E Moutet